Program
tisotumab vedotin
Also written as “Tisotumab Vedotin”, “TIVDAK” and “Tisotumab Vedotin (HuMax-TF-ADC)”.
Its studies are mostly in Uterine Cervical Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms · Neoplasm Metastasis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 92 open or running | phase 4since Apr 15, 2025 | Nov 14, 2013 | Dec 13, 2028phase 4 · NCT06952660 |
| Genmab | 10 open or running | phase 2since Mar 29, 2019 | Mar 29, 2019 | none ahead |
| Zai Lab | 10 open or running | phase 1since Apr 27, 2023 | Apr 27, 2023 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2013First study: phase 2 study in Ovarian NeoplasmsNew to PfizerPfizer · NCT02001623 · 195 enrolled · United States, Belgium, Denmark and more
- Sep 14, 2015Phase 2 study in Ovarian NeoplasmsPfizer · NCT02552121 · 33 enrolled · United States, Belgium, Denmark and more
- Aug 8, 2017Phase 2 study in Ovarian NeoplasmsPfizer · NCT03245736 · 5 enrolled · United States, United Kingdom
- Feb 8, 2018Phase 2 study in Uterine Cervical NeoplasmsPfizer · NCT03438396 · 102 enrolled · United States, Belgium, Czechia and more
- Mar 8, 2018Phase 2 study in Colorectal NeoplasmsPfizer · NCT03485209 · 350 enrolled · United States, Canada, France and more
- Aug 22, 2018Phase 2 study in Ovarian NeoplasmsPfizer · NCT03657043 · 98 enrolled · United States, Belgium, Denmark and more
- Dec 13, 2018Phase 2 study in Uterine Cervical NeoplasmsPfizer · NCT03786081 · 214 enrolled · United States, Belgium, Czechia and more
- Mar 29, 2019Genmab's first study: phase 2 study in Uterine Cervical NeoplasmsNew to GenmabGenmab · NCT03913741 · 23 enrolled · Japan
- Jan 4, 2021Phase 3 study in Uterine Cervical NeoplasmsPfizer · NCT04697628 · 502 enrolled · United States, Argentina, Austria and more
- Apr 27, 2023Zai Lab's first study: phase 1 study in Neoplasm MetastasisNew to Zai LabZai Lab · NCT05866354 · 19 enrolled · China
- Apr 15, 2025Phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT06952660 · 100 planned · United States, Puerto Rico
Ahead
- Dec 13, 2028Primary completion: phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT06952660
TargetBeta
“An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, ”NCIt, by rule
“Coagulation factor III binding agent”ChEMBL 37, by rule
Other programs on F3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-TF/TOP1i Antibody-drug Conjugate XNW28012rule | Evopoint Biosciences | phase 3 | 3 |
| Anti-TF Antibody-drug Conjugate MRG004Arule | lepu-biopharma-co-ltd | phase 3 | 2 |
| SHR-4375 | Jiangsu HengRui Medicine | phase 2 | 2 |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 1 |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | sutro-biopharma-inc | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06952660Uterine Cervical Neoplasms · United States, Puerto Rico | 4 | Recruiting | Pfizer | Dec 13, 2028 | 100 |
| NCT05866354Neoplasm Metastasis · China | 1 | Completed | Zai Lab | Nov 2, 2023 | 19 |
| NCT04697628Uterine Cervical Neoplasms · United States, Argentina, Austria and more | 3 | Completed | Pfizer | Jul 24, 2023 | 502 |
| NCT03913741Uterine Cervical Neoplasms · Japan | 2 | Completed | Genmab | Aug 14, 2020 | 23 |
| NCT03786081Uterine Cervical Neoplasms · United States, Belgium, Czechia and more | 2 | Terminated | Pfizer | Mar 19, 2026 | 214 |
| NCT03657043Ovarian Neoplasms · United States, Belgium, Denmark and more | 2 | Completed | Pfizer | Feb 8, 2022 | 98 |
| NCT03485209Colorectal Neoplasms · United States, Canada, France and more | 2 | Active, not recruiting | Pfizer | Mar 20, 2026 | 350 |
| NCT03438396Uterine Cervical Neoplasms · United States, Belgium, Czechia and more | 2 | Completed | Pfizer | Feb 6, 2020 | 102 |
| NCT03245736Ovarian Neoplasms · United States, United Kingdom | 2 | Completed | Pfizer | Jan 10, 2019 | 5 |
| NCT02552121Ovarian Neoplasms · United States, Belgium, Denmark and more | 2 | Completed | Pfizer | Dec 13, 2017 | 33 |
| NCT02001623Ovarian Neoplasms · United States, Belgium, Denmark and more | 2 | Completed | Pfizer | May 2, 2019 | 195 |
How it is read
Names in the registry
- “tisotumab vedotin”, 5 entries
- “Tisotumab Vedotin”, 3 entries
- “TIVDAK”, 1 entry
- “Tisotumab Vedotin (HuMax-TF-ADC)”, 1 entry
- “Tisotumab vedotin (HuMax-TF-ADC)”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 5 studies
- Ovarian Neoplasms, 4 studies
- Colorectal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.